

March 25, 2015



# Titan Pharmaceuticals Schedules Conference Call to Review Fourth Quarter and Full Year 2014 Financial Results

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 03/25/15 -- [Titan Pharmaceuticals, Inc.](http://www.titanpharm.com) (OTCBB: TTNP) today announced that it will host a live conference call at 10 a.m. PT / 1 p.m. ET on Wednesday, April 1, 2014 to discuss the company's financial results as of December 31, 2014. The call will be hosted by Sunil Bhonsle, president; Kate Glassman Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance, and Marc Rubin, M.D., executive chairman. Highlights of the fourth quarter and full year financial results will be included in a press release to be issued prior to the call.

The live webcast of the call may be accessed by visiting the Titan website at [www.titanpharm.com](http://www.titanpharm.com). The call can also be accessed by dialing the call-in number and participant code (also available at [www.titanpharm.com](http://www.titanpharm.com)) five minutes prior to the start time. A replay of the call will be available on the company website approximately two hours after completion of the call and will be archived for two weeks.

## **About Titan Pharmaceuticals**

Titan Pharmaceuticals Inc. (OTCBB: TTNP), based in South San Francisco, CA, is a specialty pharmaceutical company developing proprietary therapeutics primarily for the treatment of serious medical disorders. The company's lead product candidate is Probuphine®, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. Probuphine employs Titan's proprietary drug delivery system ProNeura™, which is capable of delivering sustained, consistent levels of medication for six months or longer. Titan has granted North American commercial rights for Probuphine to Braeburn Pharmaceuticals. If approved, Probuphine would be the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. The ProNeura technology has the potential to be used in developing products for treating other chronic conditions, such as Parkinson's disease, where maintaining consistent blood levels of a dopamine agonist may benefit the patient and improve medical outcomes. For more information about Titan, please visit [www.titanpharm.com](http://www.titanpharm.com).

*The press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, adverse side effects or*

*inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product development or commercialization, the uncertainty of patent protection for the Company's intellectual property or trade secrets, and the Company's ability to obtain additional financing. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release.*

**CONTACT:**

***For Investors:***

Titan Pharmaceuticals, Inc.  
Sunil Bhonsle  
(650) 244-4990  
President

***For Media:***

Susan Thomas  
(619) 540-9195  
[stthomas@titanpharm.com](mailto:stthomas@titanpharm.com)

Source: Titan Pharmaceuticals, Inc.